Insmed Inc (INSM) carries a ŷRobot AI score of 28 out of 100. The model's fair value estimate is $88.44, 23.5% below the last close of $115.63. The chart signal reads Bearish.
| Metric | INSM |
|---|---|
| AI score | 28 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $88.44 |
| Upside to fair value | -23.5% |
| Previous close | $115.63 |
| P/E | -30.30 |
| Price / sales | 23.38 |
| Market cap | $25.70B |
| EPS | -4.02 |
| Revenue growth | 30.0% |
| 1-year price change | -25.7% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 29, 2026, ŷRobot's fair-value model estimates Insmed Inc (INSM) at $88.44 against a last close of $115.63, implying 23.5% downside to the model's estimate.
The chart-signal model classifies INSM as Neutral as of Sep 29, 2026, with a signal score of -0.07 on a -1 to 1 scale.
INSM scores 28 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
INSM trades at -30.3 times earnings and 23.4 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for INSM reads -5.0% at 30 days, -4.7% at 90 days, and -25.7% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
Insmed Inc's revenue growth is +30.0% and free-cash-flow growth is -59.6% on the latest reported figures.
INSM chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.